Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.

Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, ECOSPOR IV Investigators

Open source

DOI: 10.1001/jamanetworkopen.2022.55758
Published: 2023 Feb 1
Container: JAMA network open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamanetworkopen.2022.55758,
  title = {Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.},
  author = {Sims MD and Khanna S and Feuerstadt P and Louie TJ and Kelly CR and Huang ES and Hohmann EL and Wang EEL and Oneto C and Cohen SH and Berenson CS and Korman L and Lee C and Lashner B and Kraft CS and Ramesh M and Silverman M and Pardi DS and De A and Memisoglu A and Lombardi DA and Hasson BR and McGovern BH and von Moltke L and ECOSPOR IV Investigators},
  year = {2023},
  journal = {JAMA network open},
  doi = {10.1001/jamanetworkopen.2022.55758},
  url = {https://doi.org/10.1001/jamanetworkopen.2022.55758}
}

RIS

TY  - JOUR
TI  - Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
AU  - Sims MD
AU  - Khanna S
AU  - Feuerstadt P
AU  - Louie TJ
AU  - Kelly CR
AU  - Huang ES
AU  - Hohmann EL
AU  - Wang EEL
AU  - Oneto C
AU  - Cohen SH
AU  - Berenson CS
AU  - Korman L
AU  - Lee C
AU  - Lashner B
AU  - Kraft CS
AU  - Ramesh M
AU  - Silverman M
AU  - Pardi DS
AU  - De A
AU  - Memisoglu A
AU  - Lombardi DA
AU  - Hasson BR
AU  - McGovern BH
AU  - von Moltke L
AU  - ECOSPOR IV Investigators
PY  - 2023
JO  - JAMA network open
DO  - 10.1001/jamanetworkopen.2022.55758
UR  - https://doi.org/10.1001/jamanetworkopen.2022.55758
ER  -

APA

MD, S., S, K., P, F., TJ, L., CR, K., ES, H., EL, H., EEL, W., C, O., SH, C., CS, B., L, K., C, L., B, L., CS, K., M, R., M, S., DS, P., A, D., A, M., DA, L., BR, H., BH, M., L, V. M., & Investigators, E. I. (2023). Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2022.55758

Source records

pubmed · retrieved 2026-09-26T07:52:23.829Z